Early Initiation and Long-Term Use of Vaginal Progesterone may Cause Gestational Diabetes Mellitus

Abstract

Background Preterm birth (PTB) is an important cause of neonatal mortality and morbidity. Spontaneous PTB (sPTB) is the most common cause of PTB. In patients with a singleton pregnancy, progesterone treatment appears to reduce the rate of spontaneous preterm birth in those with a previous history of spontaneous preterm labor and/or cervical shortening in the current pregnancy. Progesterone therapies used for the prevention of sPTB may increase the risk of gestational diabetes mellitus (GDM) towards the end of pregnancy owing to their effects on carbohydrate metabolism.

Aim We aimed to show the effects of vaginal progesterone use, starting time, and duration of treatment on GDM.

Methods A retrospective cohort study was carried out in pregnant women 18 to 39 years old who came to our hospital between January 1, 2021, and August 31, 2021, and who had a 2-hour 75-g oral glucose tolerance test (OGTT) at 24 to 28 weeks of gestation. In a total of 540 patients, 68 were diagnosed with GDM based on at least one abnormal plasma glucose value at screening. The remaining 472 patients with normal plasma glucose levels were considered as the control group. The groups were compared in terms of age, parity, pre-pregnancy body mass index (BMI), smoking, gestational age, and vaginal progesterone use. Patients using vaginal progesterone with and without GDM were then compared again in terms of indications for vaginal progesterone use, initiation time of progesterone therapy, duration of progesterone use, and cervical length.

Results The incidence of GDM in our study group was 12.5%. Despite the use of vaginal progesterone at a higher rate in the GDM group than in the control group (23.5 vs. 13.9%; p=0.07), it was not statistically significant. When we examined patients using progesterone as a subgroup analysis, the mean time to start vaginal progesterone treatment was 19.8±2.6 (14–24), and it was significantly earlier in the GDM group (18.1±2.0 vs. 20.2±2.6; p=0.007). Initiation of vaginal progesterone before 20 weeks of gestation was statistically significantly more frequent in the GDM group than the control group (68.8 vs. 39.4%; p=0.050 OR :3.3, 95%CI: 1.0–10.8). The mean duration of vaginal progesterone use was 50.0±15.6 days (28–90) and it was longer in the GDM group (57.8±13.4 vs. 48.1±15.6; p=0.027).

Conclusion Since the duration of vaginal progesterone use will be prolonged, there may be a risk of GDM, especially in patients who started vaginal progesterone before the 20th week of pregnancy. Even if the OGTT test performed between 24–28 weeks is normal, it should be kept in mind that these patients may have GDM in the later weeks of pregnancy, and repeating the OGTT test should be considered if necessary.

Key words

prematurity - uterine cervix - hyperglycemia - oral glucose tolerance test - spontaneous preterm birth - progestogens

Publication History

Received: 25 September 2021

Accepted: 03 January 2022

Article published online:
18 February 2022

• References

• 1 Walani SR. Global burden of preterm birth. Int J Gynaecol Obstet 2020; 150(1): 31-33 DOI: 10.1002/ijgo.13195.
• 2 Esplin MS, O‘Brien E, Fraser A. et al. Estimating recurrence of spontaneous preterm delivery. Obstet Gynecol 2008; 112(3): 516-523 DOI: 10.1097/AOG.0b013e318184181a.
• 3 Laughon SK, Albert PS, Leishear K. et al. The NICHD Consecutive Pregnancies Study: recurrent preterm delivery by subtype. Am J Obstet Gynecol 2014; 210(2): 131.e1-131.e1318 DOI: 10.1016/j.ajog.2013.09.014.
• 4 Yamashita M, Hayashi S, Endo M. et al. Incidence and risk factors for recurrent spontaneous preterm birth: a retrospective cohort study in Japan. J Obstet Gynaecol Res 2015; 41 (11) 1708-1714 DOI: 10.1111/jog.12786.
• 5 Owen J, Yost N, Berghella V. et al. Can shortened midtrimester cervical length predict very early spontaneous preterm birth?. Am J Obstet Gynecol 2004; 191(1): 298 –303. doi: 10.1016/j.ajog.2003.11.025
• 6 Berghella V, Roman A, Daskalakis C. et al. Gestational age at cervical length measurement and incidence of preterm birth. Obstet Gynecol 2007; 110(2 Pt 1): 311 –317. doi: 10.1097/01.AOG.0000270112.05025.1d
• 7 EPPPIC Group. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet 2021; 397(10283): 1183 –1194. doi: 10.1016/S0140-6736(21)00217-8
• 8 ACOG Practice Advisory: Clinical Guidance for the Integration of the Findings of the EPPPIC Meta-Analysis: Evaluating Progestogens for Preventing Preterm Birth International Collaborative https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/03/clinical-guidance-for-the-integration-of-the-findings-of-the-epppic-meta-analysis-evaluating-progestogens-for-preventing-preterm-birth-international-collaborative (Accessed on April 01, 2021)
• 9 American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Obstetrics. Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234. Obstet Gynecol 2021; 138(2): e65 –e90. doi: 10.1097/AOG.0000000000004479
• 10 Guariguata L, Linnenkamp U, Beagley J. et al. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract 2014; 103(2): 176 –185. doi: 10.1016/j.diabres.2013.11.003
• 11 Sacks DA, Hadden DR, Maresh M. et al. HAPO Study Cooperative Research Group. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care 2012; 35(3): 526-528
• 12 Plows JF, Stanley JL, Baker PN. et al. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci 2018; 19(11): 3342 DOI: 10.3390/ijms19113342.
• 13 Pergialiotis V, Bellos I, Hatziagelaki E. et al. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis. Am J Obstet Gynecol 2019; 221(5): 429 –436.e5. doi: 10.1016/j.ajog.2019.05.033
• 14 Zipori Y, Lauterbach R, Matanes E. et al. Vaginal progesterone for the prevention of preterm birth and the risk of gestational diabetes. Eur J Obstet Gynecol Reprod Biol 2018; 230: 6-9 DOI: 10.1016/j.ejogrb.2018.09.011.
• 15 Rosta K, Ott J, Kelemen F. et al. Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case-control study. Arch Gynecol Obstet 2018; 298(6): 1079-1084 DOI: 10.1007/s00404-018-4895-1.
• 16 Metzger BE, Gabbe SG, Persson B. et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33(3): 676-682 . doi: 10.2337/dc09-1848
• 17 Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: A World Health Organization Guideline. Diabetes Res Clin Pract 2014; 103(3): 341-363 DOI: 10.1016/j.diabres.2013.10.012.
• 18 Newman RB, Goldenberg RL, Iams JD. et al. Preterm prediction study: comparison of the cervical score and Bishop score for prediction of spontaneous preterm delivery. Obstet Gynecol 2008; 112(3): 508 –515. doi: 10.1097/AOG.0b013e3181842087
• 19 Daskalakis G, Goya M, Pergialiotis V. et al. Prevention of spontaneous preterm birth. Arch Gynecol Obstet 2019; 299(5): 1261-1273 . doi: 10.1007/s00404-019-05095-y
• 20 Norman JE, Marlow N, Messow CM. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. [published correction appears in Lancet. 2019 Jan 19;393(10168):228] [published correction appears in Lancet. 2019 Apr 20;393(10181):1596]. Lancet 2016; 387(10033): 2106-2116 DOI: 10.1016/S0140-6736(16)00350-0.
• 21 Eke AC, Sheffield J, Graham EM. 17α-Hydroxyprogesterone caproate and the risk of glucose intolerance in pregnancy: a systematic review and meta-analysis. Obstet Gynecol 2019; 133(3): 468-475 DOI: 10.1097/AOG.0000000000003115.
• 22 Weissman A, Drugan A. Glucose tolerance in singleton, twin and triplet pregnancies. J Perinat Med 2016; 44(8): 893-897 DOI: 10.1515/jpm-2016-0186.
• 23 Rosta K, Al-Bibawy K, Al-Bibawy M. et al. Vaginal progesterone has no diabetogenic potential in twin pregnancies: a retrospective case-control study on 1686 pregnancies. J Clin Med 2020; 9(7): 2249 DOI: 10.3390/jcm9072249.
• 24 Norman JE, Marlow N, Messow CM. et al. Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM). Health Technol Assess 2018; 22(35): 1-304 DOI: 10.3310/hta22350.
• 25 Egerman R, Ramsey R, Istwan N. et al. Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate. J Obes 2014; 2014: 563243 DOI: 10.1155/2014/563243.